切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2022, Vol. 11 ›› Issue (05) : 503 -507. doi: 10.3877/cma.j.issn.2095-3232.2022.05.015

临床研究

三维重建在中晚期肝癌转化切除中的应用
干宸鑫1, 王兴1, 潘耀振2,()   
  1. 1. 550025 贵阳,贵州医科大学临床医学院
    2. 550004 贵阳,贵州医科大学附属医院肝胆外科
  • 收稿日期:2022-06-05 出版日期:2022-10-10
  • 通信作者: 潘耀振
  • 基金资助:
    国家自然科学基金-地区科学基金([2019]81960535); 贵州省科技计划项目-黔科合支撑([2021]一般444)

Application of three-dimensional reconstruction in conversion resection of advanced primary liver cancer

Chenxin Gan1, Xing Wang1, Yaozhen Pan2,()   

  1. 1. Clinical Medicine School of Guizhou Medical University, Guiyang 550025, China
    2. Department of Hepatobiliary Surgery, the Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China
  • Received:2022-06-05 Published:2022-10-10
  • Corresponding author: Yaozhen Pan
引用本文:

干宸鑫, 王兴, 潘耀振. 三维重建在中晚期肝癌转化切除中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2022, 11(05): 503-507.

Chenxin Gan, Xing Wang, Yaozhen Pan. Application of three-dimensional reconstruction in conversion resection of advanced primary liver cancer[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2022, 11(05): 503-507.

目的

探讨三维重建在中晚期原发性肝癌(肝癌)转化切除中的应用价值。

方法

回顾性分析2019年12月至2020年7月贵州医科大学附属医院收治的2例中晚期肝癌患者临床资料。患者均签署知情同意书,符合医学伦理学规定。例1男,52岁,因"反复上腹部疼痛3个月"入院。右上腹压痛阳性。上腹部增强CT:肝Ⅴ、Ⅵ段肝细胞癌。入院初步诊断:肝癌,中国肝癌分期(CNLC)Ⅲa期。例2女,58岁,因"体检发现肝占位5 d"入院。上腹部增强CT:肝Ⅶ、Ⅷ段肝癌并周围多发子灶形成伴门静脉右支受侵。入院初步诊断:肝癌,CNLCⅢa期。2例患者术前均行CT三维重建评估,右半肝切除手术风险极大,故行TACE联合抗HBV等转化治疗。

结果

例1患者行2周期TACE治疗后复查上腹部CT示肿瘤体积缩小,肿瘤对静脉压迫改善。例2患者行3周期TACE治疗后复查上腹部CT示肿瘤体积显著缩小,肿瘤对门静脉右支压迫减轻。CT三维重建后评估可行肝癌肝切除。2例患者分别行肝癌Ⅴ、Ⅵ段切除术和Ⅶ、Ⅷ段切除术。术后行TACE辅助治疗。2例患者均未发生急性肝衰竭、胆漏、小肝综合征等术后并发症,且随访满1年均未发现肿瘤复发转移。

结论

三维重建能提供客观数据评估中晚期肝癌患者初始手术方案风险和转化治疗效果,同时指导手术方案设计。

Objective

To evaluate the application value of three-dimensional reconstruction in the conversion resection of advanced primary liver cancer (PLC).

Methods

Clinical data of 2 patients with advanced PLC admitted to the Affiliated Hospital of Guizhou Medical University from December 2019 to July 2020 were retrospectively analyzed. The informed consents of 2 patients were obtained and the local ethical committee approval was received. Patient 1: male, aged 52, was admitted to our hospital due to "recurrent upper abdominal pain for 3 months". The right upper quadrant tenderness was reported. Contrast-enhanced CT scan of the upper abdomen detected hepatocellular carcinoma in segment Ⅴ and Ⅵ. The patient was initially diagnosed with China Liver Cancer Staging (CNLC) Ⅲa liver cancer. Patient 2: female, aged 58, was admitted to our hospital due to "space-occupying lesion of the liver for 5 d during physical examination". Contrast-enhanced CT scan of the upper abdomen detected liver cancer in segment Ⅶ and Ⅷ complicated with multiple surrounding foci and involvement of the right branch of portal vein. The initial diagnosis was CNLC Ⅲa liver cancer. Preoperative evaluation were performed in 2 patients with CT three-dimensional reconstruction, which indicated a high risk for right hemihepatectomy. Therefore, TACE combined with anti-HBV conversion therapies were adopted.

Results

After 2 courses of TACE, CT scan of the upper abdomen showed that the tumor volume was decreased and the venous compression was alleviated in patient 1. For patient 2, CT scan of the upper abdomen revealed that the tumor volume was significantly reduced and the relationship between the tumor and the right branch of portal vein compression was alleviated after 3 courses of TACE. CT three-dimensional reconstruction indicated that it was feasible to perform hepatectomy afterward.2 patients underwent resection of segment Ⅴ and Ⅵ, Ⅶ and Ⅷ, respectively. Postoperative TACE adjuvant therapy was given. No postoperative complications, such as acute liver failure, bile leakage and small liver syndrome occurred in two patients. No tumor recurrence or metastasis was reported during 1-year follow-up.

Conclusions

Three-dimensional reconstruction can provide objective information to evaluate the risk of initial surgical regimen and the efficacy of conversion therapy for patients with advanced PLC, and help to make the surgical plan.

图1 例1患者肝癌转化治疗前后CT检查图注:a、b、c示转化治疗前,门静脉右前及右后分支受肿瘤压迫,存在局部浸润可能;d、e、f示转化治疗后,肿瘤较前缩小,局部血管压迫解除
表1 两例肝癌患者入院时实验室检查结果
图2 例2患者肝癌转化治疗前后CT检查图注:a、b、c示转化治疗前,肿瘤体积巨大,与周围血管边界不清;d、e、f示转化治疗后,肿瘤较前明显减小,肿瘤内部碘油沉积,其中d示肝右静脉与肿瘤关系较紧密,e示肿瘤已与门静脉分支距离较远
表2 两例肝癌患者转化治疗前后三维重建数据比较
图3 两例肝癌患者转化治疗后三维重建模型注:a为例1,肿瘤位于Ⅴ、Ⅵ段;b为例2,肿瘤位于Ⅶ、Ⅷ段,且紧贴膈肌,周围可见卫星病灶
[1]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2]
Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study[J]. Liver Int, 2015, 35(9):2155-2166.
[3]
Shi F, Lian S, Mai Q, et al. Microwave ablation after downstaging of hepatocellular carcinoma: outcome was similar to tumor within Milan criteria[J]. Eur Radiol, 2020, 30(5):2454-2462.
[4]
Affonso BB, Galastri FL, da Motta Leal Filho JM, et al. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging[J]. World J Gastroenterol, 2019, 25(37):5687-5701.
[5]
Hamaoka M, Kobayashi T, Kuroda S, et al. Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: a retrospective cohort study[J]. Int J Surg, 2017(44):223-228.
[6]
Galle PR, Tovoli F, Foerster F, et al. The treatment of intermediate stage tumours beyond TACE: from surgery to systemic therapy[J]. J Hepatol, 2017, 67(1):173-183.
[7]
方驰华, 张鹏, 周伟平,等. 三维可视化技术用于1 665例原发性肝癌精准诊治的多中心回顾性研究[J]. 中华外科杂志, 2020, 58(5):375-382.
[8]
Fang C, An J, Bruno A, et al. Consensus recommendations of three-dimensional visualization for diagnosis and management of liver diseases[J]. Hepatol Int, 2020, 14(4):437-453.
[9]
Rhu J, Kim MS, Kim S, et al. Application of three-dimensional printing for intraoperative guidance during liver resection ofa hepatocellular carcinoma with sophisticated location[J]. Ann Hepatobiliary Pancreat Surg, 2021, 25(2):265-269.
[10]
Igami T, Nakamura Y, Oda M, et al. Application of three-dimensional print in minor hepatectomy following liver partition between anterior and posterior sectors[J]. ANZ J Surg, 2018, 88(9):882-885.
[11]
陈攀, 谢威, 陈杰, 等. 自主设计3D打印截肝导板在肝癌切除手术中的初步应用[J].中华肝胆外科杂志, 2019, 25(9):641-644.
[12]
Wang K, Guo WX, Chen MS, et al. Multimodality treatment for hepatocellular carcinoma with portal vein tumor thrombus: a large-scale, multicenter, propensity mathching score analysis[J]. Medicine, 2016, 95(11):e3015.
[13]
Finn RS, Ikeda M, Zhu AX, et al. Phase Ⅰb study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2020, 38(26):2960-2970.
[14]
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 中华消化外科杂志, 2020, 19(1):1-20.
[15]
Lau WY, Lai EC. Salvage surgery following downstaging of unresectable hepatocellular carcinoma-a strategy to increase resectability[J]. Ann Surg Oncol, 2007, 14(12):3301-3309.
[16]
中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20(6):600-616.
[17]
Alrashidi I, Chu HH, Kim JH, et al. Combined chemoembolization and radiotherapy versus chemoembolization alone for hepatocellular carcinoma invading the hepatic vein or inferior vena cava[J]. Cardiovasc Intervent Radiol, 2021, 44(7):1060-1069.
[18]
Lee WH, Byun HK, Choi JS, et al. Liver-directed combined radiotherapy as a bridge to curative surgery in locally advanced hepatocellular carcinoma beyond the Milan criteria[J]. Radiother Oncol, 2020(152):1-7.
[19]
Lyu N, Kong Y, Mu L, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1):60-69.
[20]
Goto Y, Hisaka T, Sakai H, et al. Salvage surgery for initially unresectable locally advanced hepatocellular carcinoma downstaged by hepatic arterial infusion chemotherapy[J]. Anticancer Res, 2020, 40(8):4773-4777.
[21]
Irtan S, Chopin-Laly X, Ronot M, et al. Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection[J]. Liver Int, 2011, 31(5):740-743.
[22]
赵頔, 叶进冬, 李华丽, 等. 肝脏三维可视化重建技术在儿童复杂肝母细胞瘤肝切除术中的应用价值[J]. 临床肝胆病杂志, 2021, 37(9):2130-2135.
[1] 高俊颖, 张海洲, 区泓乐, 孙强. FOLFOX-HAIC 为基础的肝细胞癌辅助转化治疗的应用进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 457-463.
[2] 钟锴, 蒋铁民, 张瑞青, 吐尔干艾力·阿吉, 邵英梅, 郭强. 加速康复外科在肝囊型棘球蚴病肝切除术中的应用分析[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 425-429.
[3] 冷建军, 朴成林, 司振铎. 胰十二指肠切除术联合小范围肝切除、血管切除重建[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 384-384.
[4] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[5] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[6] 冯旺, 马振中, 汤林花. CT扫描三维重建在肝内胆管细胞癌腹腔镜肝切除术中的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 104-107.
[7] 赖全友, 高远, 汪建林, 屈士斌, 魏丹, 彭伟. 三维重建技术结合腹腔镜精准肝切除术对肝癌患者术后CD4+、CD8+及免疫球蛋白水平的影响[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 651-654.
[8] 唐梅, 周丽, 牛岑月, 周小童, 王倩. ICG荧光导航的腹腔镜肝切除术临床意义[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 655-658.
[9] 杭轶, 杨小勇, 李文美, 薛磊. 可控性低中心静脉压技术在肝切除术中应用的最适中心静脉压[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 813-817.
[10] 陈伟杰, 何小东. 胆囊癌免疫靶向治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 763-768.
[11] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[12] 陆镜明, 韩大为, 任耀星, 黄天笑, 向俊西, 张谞丰, 吕毅, 王傅民. 基于术前影像组学的肝内胆管细胞癌淋巴结转移预测的系统性分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 852-858.
[13] 焦振东, 惠鹏, 金上博. 三维可视化结合ICG显像技术在腹腔镜肝切除术治疗复发性肝癌中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 859-864.
[14] 吴警, 吐尔洪江·吐逊, 温浩. 肝切除术前肝功能评估新进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 889-893.
[15] 吴雪云, 胡小军, 范应方. 肝切除术中剩余肝再生能力的评估与预测[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 894-897.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?